Communication training for doctors treating large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your treating provider is also enrolled in this communication study
- You have large B-cell lymphoma, including related types treated like large-cell lymphoma
- Your illness has relapsed or did not respond within the required treatment timeline
- You are 18 or older, and you are fluent in English (you must choose “very well” or “well”)
- You identify as Black and/or White
- You are not in hospice care, and you are well enough to complete study tasks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.